Athenex, Inc.

FREE EMAIL WATCHDOG

Get free email notifications about news in Athenex, Inc..

The service is free and you can unsubscribe at any time.

General | People (46) | Filings (58) | Investment rounds (10) | Stock | News

Industry: PHARMACEUTICAL PREPARATIONS [2834]

CIK Number: 0001300699
IRS Number: 431985966

Athenex, Inc. is a publicly traded company

Trading symbol: ATNX

Athenex, Inc. is on the market more than 5 years.

News

2017-06-21

Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought ...
GuruFocus.com
CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 25,200 shares of ATNX on 06/19/2017 at an average price of $11 a share.
Athenex Inc (ATNX) CEO Johnson Yiu Nam Lau Acquires 25200 Shares - Markets Daily

2017-06-21

Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought ...
GuruFocus.com
CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 25,200 shares of ATNX on 06/19/2017 at an average price of $11 a share.

2017-06-19

Athenex, Inc. Announces Closing of Initial Public Offering and Full-Exercise ...
Nasdaq
BUFFALO, N.Y., June 19, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the ...

2017-06-15

Athenex on deck for IPO
Seeking Alpha
The biopharmaceutical firm develops therapies for cancer using its Orascovery and Src Kinase Inhibition platforms. Orascovery is based on a P-glycoprotein (P-gp) pump inhibitor molecule called HM30181A, which improves the absorption of P-gp substrate ...

2017-06-14

Nasdaq Welcomes Athenex, Inc. (Nasdaq: ATNX) to The Nasdaq Stock Market
GlobeNewswire (press release)
NEW YORK, June 14, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, visited the Nasdaq ...

2017-06-14

BRIEF-Athenex Inc shares open at $12 vs IPO price of $11/share​
Reuters
Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news ...

2017-06-14

Athenex, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire (press release)
BUFFALO, N.Y., June 14, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the ...
Athenex stock rises as Buffalo biotech goes public - Buffalo News

Athenex, Inc. address

1001 MAIN STREET
SUITE 600
BUFFALO
14203

Former name

Former name of this company was Kinex Pharmaceuticals LLC, date of change: 2004-08-17.

Former name of this company was Kinex Pharmaceuticals, Inc., date of change: 2013-12-23.

Company jurisdiction

DELAWARE

Entity type

Corporation

Earliest known filing

August 2004

Latest known filing

June 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

Athenex, Inc. has 58 filings. View Athenex, Inc. filings.

Latest company events

Investment Rounds

Athenex, Inc. recieved 10 investments.

People

We have found 46 people related to Athenex, Inc..